Ph3 study of mFOLFOX6 as FIL treatment in subjects with colorectal cancer

Phase III Clinical Trial

A Randomized Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (61186372COR3001)

Indication: Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer
Trial Number: 06662786
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations